Log In
Print
BCIQ
Print
Print this Print this
 

Rencarex, girentuximab (formerly WX-G250)

  Manage Alerts
Collapse Summary General Information
Company Wilex AG
DescriptionChimeric mAb against carbonic anhydrase IX (CAIX)
Molecular Target Carbonic anhydrase IX (CAIX)
Mechanism of ActionAntibody; Antibody dependent cellular cytotoxicity (ADCC)
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationRenal cancer
Indication DetailsTreat clear cell renal cell carcinoma (RCC); Treat non-metastatic clear cell renal cell carcinoma (ccRCC); Treat renal cancer
Regulatory Designation

U.S. - Fast Track (Treat clear cell renal cell carcinoma (RCC));
U.S. - Orphan Drug (Treat renal cancer);
EU - Orphan Drug (Treat renal cancer)

Partner

Esteve S.A.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today